Tevogen Bio Holdings Inc. TVGN
6.30 USD +0.16 (+2.61%)
Regular-session close
6.30 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
5.95 Day range 6.30
3.64 52-week range 24.90
- YTD
- -61.93%
- 1 year
- -71.94%
News
globenewswire.com Tevogen Highlights Significant Liability Reduction and Continued Insider Control Loss from operations declined 17% year over year for the nine months ended September 30, 2026. WARREN, N.J.
globenewswire.com Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement Tevogen secures two extra years of capital access, with up to $28.6 million in borrowing capacity through May 2029, complementing its existing ATM program.
defenseworld.net Tevogen Bio (NASDAQ:TVGN) Stock Falls 1.6% – Time to Sell? Tevogen Bio Holdings Inc. (NASDAQ: TVGN - Get Free Report) shares dropped 1.6% during mid-day trading on Wednesday. The stock traded as low as $6.40 and last traded at $6.9990. 2,500 shares were…
globenewswire.com UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and…
globenewswire.com Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and…
globenewswire.com Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and…
globenewswire.com Tevogen Bio Holdings Inc. Becomes Tevogen Inc. WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval…
globenewswire.com Tevogen Bio Announces 2026 Annual Meeting of Stockholders WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is…
globenewswire.com Tevogen Announces Formation of a Healthcare Services Initiative William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)…
globenewswire.com Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives…
globenewswire.com Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter…
globenewswire.com Letter to Shareholders from CEO Dr. Ryan Saadi Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.
globenewswire.com Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private…
globenewswire.com Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative,…
globenewswire.com Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates…
globenewswire.com Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC…
defenseworld.net Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday Tevogen Bio (NASDAQ: TVGN - Get Free Report) will likely be releasing its results before the market opens on Wednesday, April 1st. Analysts expect Tevogen Bio to post earnings of ($0.0620) per share…
globenewswire.com Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026) WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI,…
globenewswire.com Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
globenewswire.com Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,…
